Stage IIIA non-small cell lung cancer ajcc V7
Clinical trials for Stage IIIA non-small cell lung cancer ajcc V7 explained in plain language.
Never miss a new study
Get alerted when new Stage IIIA non-small cell lung cancer ajcc V7 trials appear
Sign up with your email to follow new studies for Stage IIIA non-small cell lung cancer ajcc V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Lung cancer radiation gets a precision boost: trial aims to hit tumors harder, spare healthy tissue
Disease control OngoingThis study tests whether giving a higher radiation dose directly to the tumor, while keeping the standard dose to surrounding healthy tissue, can improve outcomes for people with stage II to IIIB non-small cell lung cancer. About 146 participants will receive either photon (IMRT)…
Matched conditions: STAGE IIIA NON-SMALL CELL LUNG CANCER AJCC V7
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Proton vs. photon: which radiation beats lung cancer best?
Disease control OngoingThis study compares two types of radiation therapy (proton and photon) combined with chemotherapy for people with stage II-IIIB non-small cell lung cancer that cannot be surgically removed. The goal is to see which approach helps patients live longer and causes fewer side effects…
Matched conditions: STAGE IIIA NON-SMALL CELL LUNG CANCER AJCC V7
Phase 3 • Sponsor: Radiation Therapy Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Lung cancer drug crizotinib tested as Post-Surgery shield
Disease control OngoingThis phase 3 trial tests whether the drug crizotinib can improve survival in people with early-stage non-small cell lung cancer that has a specific genetic change called ALK fusion. After surgery to remove the tumor, patients either take crizotinib pills or are simply observed. T…
Matched conditions: STAGE IIIA NON-SMALL CELL LUNG CANCER AJCC V7
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC